[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.] [@argenxglobal](/creator/twitter/argenxglobal) "#NEWS: The ADAPT SERON study in AChR-Ab seronegative gMG met its primary endpoint. We plan to submit an sBLA to the FDA by the end of 2025. This milestone reflects our long-term commitment to the MG community and advancing understanding of disease biology. #TogetherWeDiscover" [X Link](https://x.com/argenxglobal/status/1959935481283826138) [@argenxglobal](/creator/x/argenxglobal) 2025-08-25T11:06Z 1160 followers, XXX engagements "At @AANEMorg and @MyastheniaOrg Scientific Session we will present clinical trial and real-world data demonstrating our ongoing commitment to neuromuscular disease innovation. #AANEMinSanFran #TogetherWeDiscover" [X Link](https://x.com/argenxglobal/status/1978488368251215914) [@argenxglobal](/creator/x/argenxglobal) 2025-10-15T15:49Z 1160 followers, XXX engagements
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
@argenxglobal
"#NEWS: The ADAPT SERON study in AChR-Ab seronegative gMG met its primary endpoint. We plan to submit an sBLA to the FDA by the end of 2025. This milestone reflects our long-term commitment to the MG community and advancing understanding of disease biology. #TogetherWeDiscover"
X Link @argenxglobal 2025-08-25T11:06Z 1160 followers, XXX engagements
"At @AANEMorg and @MyastheniaOrg Scientific Session we will present clinical trial and real-world data demonstrating our ongoing commitment to neuromuscular disease innovation. #AANEMinSanFran #TogetherWeDiscover"
X Link @argenxglobal 2025-10-15T15:49Z 1160 followers, XXX engagements
/creator/twitter::1345897442601029632/posts